Jarvinen HJ, Aarnio M, Mustonen H et al.. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829–834.
Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al.. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793–4797.
Walsh T, Lee MK, Casadei S et al.. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010;107:12629–12633.
Cragun D, Radford C, Dolinsky JS et al.. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 2014;86:510–520.
LaDuca H, Stuenkel AJ, Dolinsky JS et al.. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014;16:830–837.
Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 2014;16:407–412.
Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep 2014;16:371.
Kapoor NS, Curcio LD, Blakemore CA et al.. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 2015;22:3282–3288.
- Search Google Scholar
- Export Citation
. Kapoor NS Curcio LD Blakemore CA Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 2015; 22: 3282– 3288.
Kurian AW, Hare EE, Mills MA et al.. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;32:2001–2009.
Tung N, Battelli C, Allen B et al.. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015;121:25–33.
Yurgelun MB, Allen B, Kaldate RR et al.. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 2015;149:604–613.e620.
Robson ME, Bradbury AR, Arun B et al.. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2015;33:3660–3667.
Easton DF, Pharoah PD, Antoniou AC et al.. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015;372:2243–2257.
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449–2460.
Boursi B, Sella T, Liberman E et al.. The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer 2013;49:3680–3685.
Gryfe R, Di Nicola N, Lal G et al.. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 1999;64:378–384.
Laken SJ, Petersen GM, Gruber SB et al.. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79–83.
Liang J, Lin C, Hu F et al.. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am J Epidemiol 2013;177:1169–1179.
Locker GY, Kaul K, Weinberg DS et al.. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 2006;169:33–38.
Patael Y, Figer A, Gershoni-Baruch R et al.. Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews. Eur J Hum Genet 1999;7:555–559.
Rennert G, Almog R, Tomsho LP et al.. Colorectal polyps in carriers of the APC I1307K polymorphism. Dis Colon Rectum 2005;48:2317–2321.
Shtoyerman-Chen R, Friedman E, Figer A et al.. The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. Genet Test 2001;5:141–146.
Lammi L, Arte S, Somer M et al.. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004;74:1043–1050.
Lejeune S, Guillemot F, Triboulet JP et al.. Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis. Hum Mutat 2006;27:1064.
Marvin ML, Mazzoni SM, Herron CM et al.. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A 2011;155A:898–902.
Rivera B, Perea J, Sanchez E et al.. A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia. Eur J Hum Genet 2014;22:423–426.
Wong S, Liu H, Bai B et al.. Novel missense mutations in the AXIN2 gene associated with non-syndromic oligodontia. Arch Oral Biol 2014;59:349–353.
Gronwald J, Cybulski C, Piesiak W et al.. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 2009;100:1508–1512.
Liu C, Wang QS, Wang YJ. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2012;13:2051–2055.
Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 2011;47:2546–2551.
Jaeger E, Leedham S, Lewis A et al.. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 2012;44:699–703.
Lieberman S, Walsh T, Schechter M et al.. Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance. Gastroenterology 2017;152:1876–1880.e1.
Rohlin A, Eiengard F, Lundstam U et al.. GREM1 and POLE variants in hereditary colorectal cancer syndromes. Genes Chromosomes Cancer 2016;55:95–106.
Ikeda M, Orimo H, Moriyama H et al.. Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability. Cancer Res 1998;58:594–598.
Adam R, Spier I, Zhao B et al.. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 2016;99:337–351.
Theodoratou E, Campbell H, Tenesa A et al.. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010;103:1875–1884.
Win AK, Cleary SP, Dowty JG et al.. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 2011;129:2256–2262.
Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011;10:1–9.
Win AK, Dowty JG, Cleary SP et al.. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 2014;146:1208–1211.e1–5.
Rosner G, Bercovich D, Daniel YE et al.. Increased risk for colorectal adenomas and cancer in mono-allelic MUTYH mutation carriers: results from a cohort of North-African Jews. Fam Cancer 2015;14:427–436.
Weren RD, Ligtenberg MJ, Kets CM et al.. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 2015;47:668–671.
Garg P, Burgers PM. DNA polymerases that propagate the eukaryotic DNA replication fork. Crit Rev Biochem Mol Biol 2005;40:115–128.
Bellido F, Pineda M, Aiza G et al.. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med 2016;18:325–332.
Palles C, Cazier JB, Howarth KM et al.. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136–144.
Valle L, Hernandez-Illan E, Bellido F et al.. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 2014;23:3506–3512.
Elsayed FA, Kets CM, Ruano D et al.. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet 2015;23:1080–1084.
Spier I, Holzapfel S, Altmuller J et al.. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 2015;137:320–331.
Esteban-Jurado C, Gimenez-Zaragoza D, Munoz J et al.. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 2017;8:26732–26743.